孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究

doi:10.3969/j.issn.1006-7795.2015.04.007

首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (4): 548-552.doi: 10.3969/j.issn.1006-7795.2015.04.007

• 更年期与妇科生殖内分泌 • 上一篇下一篇

孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究

张颖¹, 阮祥燕^1,2, 米鑫³, 王刚乐⁴, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院内分泌与绝经中心, 图宾根-72076, 德国;
3. 顺义区妇幼保健院, 北京 100026;
4. 首都医科大学附属北京妇产医院乳腺外科, 北京 100026

收稿日期:2015-05-22 出版日期:2015-08-21 发布日期:2015-07-17
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
国家自然科学基金项目(81172518),北京市科技新星交叉合作项目(Z14111000180000),北京市卫生系统高层次卫生技术人才培养计划项目(2014-2-016),首都医科大学附属北京妇产医院学科带头人项目(2013-1)。

Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients

Zhang Ying¹, Ruan Xiangyan^1,2, Mi Xin³, Wang Gangyue⁴, Alfred O. Mueck^1,2

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. University Women's Hospital of Tuebingen, Tuebingen 72076, Germany;
3. Shunyi Obstetrics and Gynecology Hospital, Beijing 100026, China;
4. Department of Breast Surgery, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

Received:2015-05-22 Online:2015-08-21 Published:2015-07-17
Supported by:
This study was supported by National Natural Science Foundation of China(81172518); Beijing Nova Program(Z14111000180000); Beijing Municipality Health Technology High-level Talent(2014-2-016); Project of Discipline Leader, Beijing Obstetrics and Gynecology Hospital, Capital Medical University(2013-1).

摘要/Abstract

摘要：

目的探讨孕激素受体膜组分1(progesterone receptor membrane component 1,PGRMC1)在乳腺癌患者预后方面的作用及临床意义,为评估患者预后提供更多的预测依据。方法试验纳入2008年1月1日至2014年12月31日间初诊诊断为乳腺癌的患者50例,记录患者年龄、肿瘤直径、病理分级、淋巴结转移等预后相关因素,追踪随访患者预后情况,免疫组织化学方法检测乳腺癌组织标本雌激素受体α(estrogen receptor α,ERα)、孕激素受体(progesterone receptor,PR)、Ki67、PGRMC1表达情况,并分析与患者预后之间的相关性。结果纳入试验的50名女性乳腺癌患者,乳腺癌组织ERa阳性表达率为48.0%,共24例;PR阳性表达率为42.0%,共21例;Ki67阳性表达率为4%,共2例;PGRMC1阳性表达率为70.0%,共35例。PGMRC1的表达与年龄、肿瘤病理分级之间无明显相关性,与肿瘤直径、淋巴结转移间有明显相关性(OR=1.60,95%CI:1.11~2.29;OR=1.12,95%CI:1.02~1.23),PGRMC1表达阳性程度越高,患者复发可能性越大(P=0.011),远期生存情况越差(P=0.028)。结论 PGRMC1与常见预后因子肿瘤直径、淋巴结转移间存在关联,与患者疾病复发、远期生存情况存在关联,其很有可能成为乳腺癌患者预后的独立预测因子。

关键词: 乳腺癌, 孕激素受体膜组分1, 雌激素受体, 预后因子

Abstract:

Objective The aim of this study was to investigate the potential clinical prognosis significance of progesterone receptor membrane component 1(PGRMC1) for breast cancer patients. Methods Fifty cases of breast cancer patients were derived from the Beijing Obstetrics and Gynecology hospital, Capital Medical University from Jan. 2008 to Dec 2014. Clinical and pathological data in details, such as date of primary diagnosis date, age, histologic grade, tumor size, lymph node metastasis, and patient follow-up information were collected and retrospectively analyzed. Immunohistochemical staining were carried out manually to evaluated the expression of estrogen receptor α(ERa)、progesterone receptor(PR)、Ki67 and PGRMC1 in breast cancer samples. Results For all the 50 tissues, the hormonal receptor status was 48.0% ERα positive(n=24), 42.0% PR positive(n=21), 4% Ki67 positive(n=2). Of the samples, 70.0%(n=35) were PGRMC1 positive. The result showed one statistically significant correlation, between PGRMC1 and tumor size, lymph node metastas(OR=1.60, 95%CI: 1.11-2.29; OR=1.12, 95%CI: 1.02-1.23). The association between conventional clinicopathological features and prognosis in breast cancer patients were evaluated. PGRMC1 expression would be used as predictors of recurrence(P=0.011) and poor overall survival(P=0.028) in breast cancer patients in Cox's proportional hazard model. Conclusion The high PGRMC1 level was associated with poor disease free survival rate and overall survival rate. PGRMC1 might be a independent prognostic factor breast cancer in the future.

Key words: breast cancer, progesterone receptor membrane component 1(PGRMC1), estrogen receptor, prognosis factor

中图分类号:

R737.9

张颖, 阮祥燕, 米鑫, 王刚乐, Alfred O. Mueck. 孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究[J]. 首都医科大学学报, 2015, 36(4): 548-552.

Zhang Ying, Ruan Xiangyan, Mi Xin, Wang Gangyue, Alfred O. Mueck. Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients[J]. Journal of Capital Medical University, 2015, 36(4): 548-552.

参考文献

[1] Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010[J]. Chin J Cancer Res, 2014,26(1):48-58.
[2] Cahill M A. Progesterone receptor membrane component 1: an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105(1-5):16-36.
[3] Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development[J]. Climacteric, 2013,16(5):509-513.
[4] Neubauer H, Seeger H, Ruan X. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J]. Menopause, 2011,18(8):845-850.
[5] Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferatiion of human breast cancer cells[J]. Climacteric, 2012,15(5):467-472.
[6] Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J]. Menopause, 2013,20(5):504-510.
[7] Neubauer H, Chen R, Schneck H, et al. Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells[J]. Horm Mol Biol Clin Investig, 2011,6(1):185-192.
[8] Crudden G, Chitti R E, Craven R J. Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J]. Pharmacol Exp Ther, 2006,316(1):448-455.
[9] Ahmed I S, Rohe H J, Twist K E, et al. Pgrmc1(progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity[J]. J Biol Chem, 2010,285(32):24775-24782.
[10] Peluso J J, Pappalardo A, Losel R, et al. Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability[J]. Biol Reprod, 2005,73(2):261-270.
[11] Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study[J]. J Clin Oncology, 2005,23(30):7512-7517.
[12] Haerslev T, Jacobsen G K, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen(PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas[J]. Breast Cancer Res Treatment, 1996,37:101-113.
[13] 张岳超,王雪梅,王丽萍.乳腺癌预后分子生物学标志物的研究进展[J].使用检验医师,2013,5(4):248-250.
[14] 崔玉洁,张凯,苏同义,等.乳腺癌分子靶向治疗研究进展[J].解放军医药杂志,2014,26(1):95-98.
[15] 李世超,姜军.乳腺癌循环肿瘤细胞生物学特性的研究进展[J].中华肿瘤防治杂志,2012,19(16):1272-1275.
[16] 徐兵河.乳腺癌的分子靶向治疗进展[J].中国医科大学学报,2013,42(12):1057-1060,1064.
[17] 曹丹霞,何建蓉,沈坤炜,等.激素受体和HER-2及Ki-67预测乳腺癌新辅助化疗疗效价值的分析[J].中华肿瘤防治杂志,2012,19(13):1000-1003.
[18] 王永南,王颀,张安秦,等.Ki-67与分子亚型预测乳腺癌新辅助化疗敏感性的研究[J].中华肿瘤防治杂志,2012,19(23):1805-1809.

孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究

Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[7]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[8]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[9]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[10]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[11]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[12]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[13]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.
[14]	李雪, 阮祥燕, 谷牧青, 蔡桂举, 赵越, Alfred O. Meuck. 孕激素受体膜组分1促进雌孕激素诱导的乳腺癌细胞增生的研究——雌二醇与周期序贯及连续联合比较[J]. 首都医科大学学报, 2019, 40(2): 237-243.
[15]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.